Cardiovascular Disease

Older patients with ischemic stroke who took statins for 2 years after discharge experienced fewer CV events after hospital discharge compared with those who took them for less than 2 years or not at all, researchers reported in Stroke.

Cholesterol testing dropped during the COVID-19 pandemic, raising concerns about providing patients with proper preventive care, according to a study published in the American Journal of Preventive Cardiology.

Adults with type 2 diabetes assigned an SGLT2 inhibitor or a GLP-1 receptor agonist during cardiovascular outcomes trials derived benefit from the therapies regardless of whether they were prescribed insulin, according to a meta-analysis.

Female physicians demonstrated better patient outcomes compared with their male counterparts due to the lower likelihood of male physicians providing guideline-recommended care to female patients, researchers reported.

The timing of moderate to vigorous physical activity bouts may improve cardiorespiratory fitness for adults with type 2 diabetes and obesity, especially for men, according to an analysis of Look AHEAD study data.

The medical community during the past year has learned, among other things, that SARS-CoV-2 has numerous short-term and long-term consequences on the CV system.

In 1952, Irene Pollin’s firstborn son, Kenneth, died of congenital heart disease at age 15 months. More than a decade later, her daughter, Linda, succumbed to the same inherited condition at age 16 years

For this issue, Cardiology Today spoke with Editorial Board Member Laxmi Mehta, MD, FACC, FAHA, FNLA. She is a noninvasive cardiologist and professor of medicine in the division of cardiovascular medicine at The Ohio State University. She holds the Sarah Ross Soter Endowed Chair in Women’s Cardiovascular Health, is the section director of preventive cardiology and women’s cardiovascular health and director of lipid clinics and is the vice chair of wellness for the department of internal medicine at Ohio State.

For Pfizer and its JAK inhibitor, Xeljanz, February rang in with the sound of alarm bells, as the FDA issued its third warning about the drug in 2 years.

COVID-19 vaccine prioritization should focus on patients with severe CVD rather than those who are well-managed, according to a health policy statement from the American College of Cardiology.